Login to Your Account



Jury favors Amgen in PCSK9 trial; Regeneron, Sanofi set to appeal

By Jennifer Boggs
Managing Editor

Wednesday, March 16, 2016

Regeneron Pharmaceuticals Inc. and partner Sanofi SA are hoping now to make their case in the Federal Circuit after a U.S. District Court jury ruled that patents covering Amgen Inc.'s competing PCSK9 antibody, Repatha (evolocumab), are valid, a decision that, if it stands, could put Regeneron and Sanofi on the hook for damages, including royalties from sales of Praluent (alirocumab).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription